Biologic dual target therapy for refractory Crohn′s disease: five cases and literature review
10.3760/cma.j.cn101480-20220214-00029
- VernacularTitle:生物制剂双靶治疗难治性克罗恩病五例并文献复习
- Author:
Yan JIA
1
;
Shaokang ZHU
;
Xianzong MA
;
Limin ZHANG
;
Shuwen DU
;
Xin FAN
;
Shirong LI
;
Peng JIN
Author Information
1. 解放军总医院第七医学中心消化内科，北京 100700
- Publication Type:Journal Article
- Keywords:
Crohn′s disease;
Biologic;
Dual target therapy;
Refractory;
Infliximab;
Ustekinumab;
Vedolizumab
- From:
Chinese Journal of Inflammatory Bowel Diseases
2022;06(3):228-234
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the short-term efficacy of dual biologics combination therapy in the treatment of refractory Crohn′s disease (CD) .Methods:The clinical features, diagnosis and treatment of 5 cases of refractory CD treated with biologics dual-target therapy in the Seventh Medical Center of Chinese PLA General Hospital between January 26, 2020 and August 15, 2021 were retrospectively analyzed. The relevant literatures were reviewed and summarized by searching the articles on biologics dual-target therapy published in MEDLINE, EMBASE and Cochrane Library until August 2021.Results:Five patients with refractory CD were all male, aged 40.8 (23.0, 56.0) years, with disease course of 10.4 (6.0, 17.0) years, including 2 patients treated with infliximab (IFX) in combination with ustekinumab (UST) . Two patients treated with IFX in combination with vedolizumab (VDZ) and 1 patient treated with UST in combination with VDZ. Laboratory and colonoscopy examinations were performed 14 weeks after combination therapy in the VDZ containing group and 16 weeks after combination therapy in the VDZ free group. Results of examinations after treatment indicated that 1 case presented clinical remission, 3 cases presented clinical response and 3 cases presented endoscopic response. Combination therapy group with UST had better efficacy. None of the 5 patients had special adverse drug reactions during follow-up for six months after combined treatment. A total of 17 relevant reports were retrieved.Conclusion:Biologic dual-target therapy may be a short-term effective and safe treatment for refractory CD.
